Company Registry

Talapo Therapeutics Inc
Profile last edited on: 7/30/2019

Obesity treatments
Year Founded
2015
First SBIR Year
2018
Latest SBIR Award
2018
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2223 Avenida De La Playa Suite 206
La Jolla, CA 92037
   (858) 248-9253
   N/A
   www.talapobio.com
Multiple Locations:   
Congressional District:   52
County:   San Diego

Public Profile

Structured around the development of cellular therapeutics designed to treat obesity, Talapo Therapeutics is employing cellular therapeutics agents to target growth factors with roles in adipogenesis. The effort is to block the cellular process of producing fat tissue thus inhibiting the storage of fat and enabling patients to get effective anti-obesity treatments.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2018 1 NIH $290,134
Targeting TGF-Beta Growth Factors to Treat Obesity
2018 1 NIH $224,980
Cerberus Therapy for Metastatic Disease

Key People / Management

  Davorka Messmer -- Chief Executive Officer

  Erik Martinez-Hackert -- Founder & CSO

  Neil Senturia -- Executive Officer & Chairman

SBIR firms in the news

There are no news available.